MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human Genetics. The study demonstrates the impact of PacBio’s HiFi long-read sequencing technology in identifying genetic causes of rare diseases, illustrating the feasibility of potentially replacing multiple diagnostic tes ...

Core Insights - PacBio reported preliminary unaudited revenue for Q4 2024 of $39.2 million, a decline of 33% year-over-year, and full-year revenue of $154.0 million, down 23% from the previous year [1][6] - The company launched the Vega benchtop system and SPRQ chemistry, aimed at making HiFi sequencing more accessible and affordable [1][7] - CEO Christian Henry expressed optimism about market share growth in 2025 and noted positive early feedback on new products [2] Business Updates - The Vega system is designed to broaden access to HiFi long-read sequencing [7] - SPRQ chemistry enables sequencing of the human genome for under $500, significantly reducing DNA input requirements [7] - PacBio has begun delivering Vega systems to Berry Genomics for prenatal health and screening programs [7] Financial Position - The company strengthened its balance sheet by exchanging $459 million in convertible senior notes for $200 million in new notes due in August 2029, along with 20.5 million shares and $50 million in cash [7] - Preliminary instrument revenue for Q4 2024 is expected to be approximately $15.3 million, down from $35.1 million in Q4 2023, with 23 Revio and 7 Vega systems sold [7] - Preliminary consumables revenue for Q4 2024 is expected to be around $18.8 million, slightly down from $18.9 million in the same period last year [7] - Total preliminary unrestricted cash and investments as of December 31, 2024, is expected to be approximately $390 million [7]

Pacific Biosciences of California, Inc. (PACB) recently delivered its first Vega systems to Berry Genomics as part of an early access agreement announced in 2022. Under the terms of the original agreement, Berry Genomics is likely to develop and optimize its targeted assays to support carrier, prenatal and newborn screening programs in China and other markets.Vega systems are advanced sequencing platforms, designed for high-throughput, precise genomic analysis. These systems utilize PacBio's HiFi sequencing ...

MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled GutID, the first commercial human gut health test powered by Intus Bio’s groundbreaking Titan-1 platform and PacBio’s HiFi sequencing technology. By combining Intus Bio’s patented strain-level resolution assay and AI-powered analysis with PacBio’s renowned sequencing accuracy, GutID sets a new ...

Partnership and Collaboration - Berry Genomics will leverage PacBio's Vega system to develop long-read sequencing-based solutions for carrier, prenatal, and newborn screening programs in China and other markets [1] - Berry Genomics will build on the Vega platform to deliver solutions tailored to the characteristics of its clinical customers and the populations they serve [2] - Berry Genomics has committed to purchasing more than 50 Vega units as part of its agreement with PacBio [2] Technology and Product Development - The Vega system is PacBio's first benchtop long-read sequencing platform, offering exceptional data accuracy with HiFi technology and fast turnaround time [4] - Vega delivers the functionality of PacBio's high-throughput Revio system in a compact, lower-throughput benchtop platform, making it suitable for laboratories with limited space and sample volumes [4] - Berry Genomics will take the resulting instrument through the NMPA regulatory review process in China and support additional product registrations in other markets [2] Market and Application Focus - Next-generation sequencing technology has shown great potential in understanding genetic diseases and interpreting the human genome to benefit human health [3] - Small to medium-sized laboratories in China require genomics equipment that is compact, affordable, and capable of processing smaller sample volumes quickly [3] - Berry Genomics aims to provide best-in-class genomics services to clinical labs, unlocking new research opportunities and expanding the application of long-read sequencing technology [3][8] Company Background - PacBio is a premier life science technology company specializing in advanced sequencing solutions, including HiFi long-read sequencing and SBB short-read sequencing technologies [5] - Berry Genomics, established in 2010 and listed on the A-share main board in 2017, focuses on transforming genetic testing technology into clinical applications, particularly in reproductive health, genetic disease testing, and oncology [7][8]

Company Performance - Pacific Biosciences of California (PACB) closed at $2, reflecting a +0.5% change from the previous day, outperforming the S&P 500's daily loss of 1.11% [1] - Over the past month, PACB shares have decreased by 8.72%, which is worse than the Medical sector's loss of 6.22% and the S&P 500's loss of 1.7% [1] Earnings Forecast - The upcoming earnings report for Pacific Biosciences is expected to show an EPS of -$0.20, representing a 25.93% increase from the same quarter last year [2] - Revenue is anticipated to be $40.9 million, indicating a 29.92% decrease compared to the same quarter last year [2] Analyst Estimates - Recent adjustments to analyst estimates for Pacific Biosciences are being closely monitored, as they often reflect changes in near-term business trends [3] - Positive changes in estimates suggest analyst optimism regarding the company's business and profitability [3] Zacks Rank and Industry Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), indicates that stocks rated 1 have delivered an average annual return of +25% since 1988 [5] - Currently, Pacific Biosciences holds a Zacks Rank of 3 (Hold), with the consensus EPS projection having decreased by 4.95% in the past 30 days [5] - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 69, placing it in the top 28% of over 250 industries [6]

Core Insights - PacBio will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 4:30 PM PT in San Francisco, California [1] - A live webcast of the presentation will be available on the company's investor page, with a replay accessible for at least 30 days post-event [2] Company Overview - PacBio is a leading life science technology company specializing in high-quality sequencing solutions aimed at resolving genetically complex problems [3] - The company utilizes two core technologies: HiFi long-read sequencing and SBB® short-read sequencing, focusing on accuracy, quality, and completeness [3] - PacBio's products cater to various research applications, including human germline sequencing, plant and animal sciences, infectious diseases, microbiology, and oncology [3]

Core Insights - The article emphasizes the importance of disciplined risk management in investment strategies, advocating for a barbell approach that allocates 90% to safe assets and 10% to high-growth opportunities [1] DCF Model Assumptions - The valuation model assumes free cash flow will grow at a constant annual rate over the next eight years, with projected cash flows discounted back to present value using a fixed discount rate derived from the Capital Asset Pricing Model (CAPM) [1] - A terminal value is calculated by projecting free cash flow into the ninth year, assuming continued growth at the same rate, and applying a perpetual growth rate using the Gordon Growth Model [1] - Key assumptions include constant growth and discount rates, with the discount rate exceeding the perpetual growth rate to ensure a finite terminal value [1]

Company Participation in Investor Conferences - PacBio will participate in several upcoming investor conferences, including the UBS Global Healthcare Conference on November 13, 2024, the Wolfe Research Healthcare Conference on November 19, 2024, the Stephens Annual Investment Conference on November 20, 2024, and the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 [1] Company Overview - PacBio is a leading life science technology company that specializes in advanced sequencing solutions aimed at resolving genetically complex problems [2] - The company’s core technologies include HiFi long-read sequencing and SBB® short-read sequencing, focusing on accuracy, quality, and completeness [2] - PacBio's products cater to a wide range of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications [2]

Core Insights - PacBio reported an adjusted loss per share of 17 cents for Q3 2024, an improvement from a loss of 27 cents in the same quarter last year, beating the Zacks Consensus Estimate by 15% [1] - Total revenues for the quarter were $40 million, down 28.2% year over year, and missed the Zacks Consensus Estimate by 4.6% [2] Revenue Breakdown - Revenues from the Americas were $20.1 million, a decline of 31% year over year, primarily due to decreased Revio shipments [3] - Asia-Pacific revenues totaled $10.8 million, reflecting a 32% year-over-year decline [3] - EMEA region revenues were $9.1 million, down 17% year over year [3] - Product revenues increased to $35.3 million, up 11.2% from the previous year [4] - Instrument revenues fell to $16.8 million, a decrease of 51.6% year over year due to lower Revio unit shipments [4] - Consumable revenues reached $18.5 million, up 9.5% from the prior year [4] - Service and other revenues amounted to $4.7 million, also up 9.5% year over year [5] Margin and Expenses - Adjusted gross profit decreased by 28.1% to $13 million, but adjusted gross margin expanded by 100 basis points year over year to 33% [6] - Sales, general and administrative expenses rose by 0.7% to $43.7 million [6] - Research and development expenses declined by 46.3% year over year to $25.5 million [6] - Adjusted total operating expenses were $62.4 million, down 31% year over year [6] Financial Position - PacBio ended Q3 2024 with cash, cash equivalents, and investments of $471.1 million, down from $509.8 million at the end of Q2 2024 [8] - The company revised its revenue outlook for 2024, expecting fourth-quarter revenues to be flat to slightly up compared to Q3 2024 [8] - Full-year revenues are anticipated to be lower than the previous estimate of $170 million, with the Zacks Consensus Estimate at $168.1 million [9] Market Performance - Despite mixed results, with earnings beating estimates but revenues missing, shares fell by 14.7% in after-market trading [10] - Year-to-date, PacBio's stock has declined by 75.1%, contrasting with the industry's 6.3% growth and the S&P 500's 24.7% increase [14]